Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.76 |
| ▸ | CD44 | P16070 | 2/20 | 0.76 |
| ▸ | MAOB | P27338 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL27957682 | 0.91 | PNMT (0.68) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28764309 | 0.88 | CD44 (0.76) | PNMTCD44MAOBHTR2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.87 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.87 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.87 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6647088 | 0.86 | PNMT (0.73) | PNMTCD44MAOBHTR2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL16291557 | 0.85 | PNMT (0.86) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 | 0.85 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4243903 | 0.85 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11213530 | 0.85 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008134071-A1 | MULTIMODAL ABUSE RESISTANT EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008033351-A2 | MULTIMODAL ABUSE RESISTANT AND EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2008024408-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS FOR APPLICATION TO THE SKIN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2008024490-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF ABUSE DETERRENT CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2008021394-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-02-21 | — | — | WO | claimed |
| US-20060034872-A1 | Compositions and methods for preventing abuse of orally administered medications | GENERAL HOSPITAL CORPORATION, THE | 2006-02-16 | — | — | US | claimed |
| WO-2003092676-A1 | COMPOSITIONS AND METHODS FOR PREVENTING ABUSE OF ORALLY ADMINISTERED MEDICATIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| EP-3045043-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2448406-B1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9125833-B2 | Multimodal abuse resistant and extended release opioid formulations | RELMADA THERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120178771-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | RELMADA THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2448406-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120065221-A1 | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use | THERAQUEST BIOSCIENCES, INC. (PA) | 2012-03-15 | — | — | US | disclosed |
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008024408-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS FOR APPLICATION TO THE SKIN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024490-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF ABUSE DETERRENT CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008021394-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20060034872-A1 | Compositions and methods for preventing abuse of orally administered medications | GENERAL HOSPITAL CORPORATION, THE | 2006-02-16 | — | — | US | disclosed |
| WO-2003092676-A1 | COMPOSITIONS AND METHODS FOR PREVENTING ABUSE OF ORALLY ADMINISTERED MEDICATIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178771-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | OPRK1, OPRM1, OPRD1 | PNMT 422/4885CD44 2270/4885MAOB 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.